GlassScriptPhysician profile
Douglas D Lehmann
NPI 1508832734
$346.82
in general payments reported to CMS, 2019-2025
13 companies · $36.48 in 2025
The $36.48 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.11 · 2022: $62.43 · 2023: $118 · 2024: $119 · 2025: $36.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73.53 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $46.56 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $39.27 | 2023-2024 | Jornay Pm |
| Lilly USA, LLC | $30.26 | 2023-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $25.03 | 2022-2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Exact Sciences Corporation | $19.98 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $17.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.75 | 2024 | Rexulti |
| Amgen INC. | $17.47 | 2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.99 | 2022 | |
| Daiichi Sankyo INC. | $15.93 | 2022 | |
| Gilead Sciences, INC. | $15.11 | 2024 | |
| Novo Nordisk INC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lehmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.